Journal of Clinical Oncology, Vol 18, Issue 15
(August), 2000: 2908-2925
© 2000 American Society for Clinical Oncology
Primary Cutaneous T-Cell Lymphoma: Review and Current Concepts
By Richard S. Siegel,
Tomi Pandolfino,
Joan Guitart,
Steven Rosen,
Timothy M. Kuzel
From the Departments of Hematology/Oncology and Dermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL.
Address reprint requests to Richard Siegel, MD, Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, 676 N St Clair, Suite 850, Chicago, IL 60611; email r_siegel{at}northwestern.edu © 2000 by American Society of Clinical Oncology. 0732-183X/00/1815-2908
ABSTRACT
PURPOSE: Primary cutaneous T-cell lymphomas (CTCLs) encompass a wide variety of lymphomas that are characterized by the localization of the malignant lymphocytes to the skin at presentation. Advances in molecular biologic techniques, including immunophenotyping and gene rearrangement studies to determine clonality, have led to more frequent diagnosis of CTCL as well as more consistent subclassification of these entities. However, there continues to be confusion in the classification, prognosis, and management of patients with CTCL. The purpose of this review is to present a summary of the diagnosis, prognosis, and treatment of CTCL, with specific emphasis on mycosis fungoides (MF) and Sézary syndrome (SS). We also present a detailed discussion of the entities that make up the differential diagnosis of CTCL.
DESIGN: We reviewed the medical literature on CTCL and other diseases that make up the differential diagnosis of CTCL.
Results and
CONCLUSION: MF and SS are the most common forms of CTCL. The etiology of this disease is still unknown. Patients may go for months to years with skin abnormalities before being diagnosed. MF/SS is an indolent disease and patients with T1 disease have a normal life expectancy. Patients who undergo transformation to large-cell lymphoma (8% to 23% of patients) have a poor prognosis, with mean survival ranging from 2 to 19 months. Treatment for MF/SS continues to be palliative. There are many new therapies that are currently being investigated in clinical trials, and the DAB389IL-2 fusion protein was recently approved for the treatment of refractory MF/SS.
This article has been cited by other articles:
|
|
|
|
 
D. Winter, J. Moser, E. Kriehuber, C. Wiesner, R. Knobler, F. Trautinger, P. Bombosi, G. Stingl, P. Petzelbauer, A. Rot, et al.
Down-Modulation of CXCR3 Surface Expression and Function in CD8+ T Cells from Cutaneous T Cell Lymphoma Patients
J. Immunol.,
September 15, 2007;
179(6):
4272 - 4282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. S. Mann, J. R. Johnson, K. He, R. Sridhara, S. Abraham, B. P. Booth, L. Verbois, D. E. Morse, J. M. Jee, S. Pope, et al.
Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma
Clin. Cancer Res.,
April 15, 2007;
13(8):
2318 - 2322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. de Quatrebarbes, E. Esteve, M. Bagot, P. Bernard, M. Beylot-Barry, M. Delaunay, M. D'Incan, P. Souteyrand, L. Vaillant, N. Cordel, et al.
Treatment of Early-Stage Mycosis Fungoides With Twice-Weekly Applications of Mechlorethamine and Topical Corticosteroids: A Prospective Study
Arch Dermatol,
September 1, 2005;
141(9):
1117 - 1120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Sachs, N. Shahab, P. A. Kaplan, D. C. Doll, and S. Haider
Conditions Suggesting Lymphoma: CASE 1. Lymphomatoid Papulosis
J. Clin. Oncol.,
June 1, 2005;
23(16):
3843 - 3844.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Assaf, M. Hummel, M. Steinhoff, C. C. Geilen, H. Orawa, H. Stein, and C. E. Orfanos
Early TCR-{beta} and TCR-{gamma} PCR detection of T-cell clonality indicates minimal tumor disease in lymph nodes of cutaneous T-cell lymphoma: diagnostic and prognostic implications
Blood,
January 15, 2005;
105(2):
503 - 510.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C Assaf, M Hummel, M Zemlin, M Steinhoff, C C Geilen, H Stein, and C E Orfanos
Transition of Sezary syndrome into mycosis fungoides after complete clinical and molecular remission under extracorporeal photophoresis
J. Clin. Pathol.,
December 1, 2004;
57(12):
1325 - 1328.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. De Francesco, F. Gargiulo, P. Esteban, P. G. Calzavara-Pinton, M. Venturini, F. Perandin, M. Baronio, C. Pollara, L. Terlenghi, and N. Manca
Polymorphism analysis of Epstein-Barr virus isolates of lymphoblastoid cell lines from patients with mycosis fungoides
J. Med. Microbiol.,
May 1, 2004;
53(5):
381 - 387.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Weidmann, M. Gramatzki, M. Wilhelm, and P. S. Mitrou
Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting
Ann. Onc.,
March 1, 2004;
15(3):
369 - 374.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tracey, R. Villuendas, A. M. Dotor, I. Spiteri, P. Ortiz, J. F. Garcia, J. L. R. Peralto, M. Lawler, and M. A. Piris
Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study
Blood,
August 1, 2003;
102(3):
1042 - 1050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Tracey, R. Villuendas, P. Ortiz, A. Dopazo, I. Spiteri, L. Lombardia, J. L. Rodriguez-Peralto, J. Fernandez-Herrera, A. Hernandez, J. Fraga, et al.
Identification of Genes Involved in Resistance to Interferon-{alpha} in Cutaneous T-Cell Lymphoma
Am. J. Pathol.,
November 1, 2002;
161(5):
1825 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Guitart, S. C. Wickless, Y. Oyama, T. M. Kuzel, S. T. Rosen, A. Traynor, and R. Burt
Long-term Remission After Allogeneic Hematopoietic Stem Cell Transplantation for Refractory Cutaneous T-Cell Lymphoma
Arch Dermatol,
October 1, 2002;
138(10):
1359 - 1365.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Visco, L. J. Medeiros, D. Jones, T. Smith, M. A. Rodriguez, P. McLaughlin, J. Romaguera, F. Cabanillas, and A. H. Sarris
Primary cutaneous non-Hodgkin's lymphoma with aggressive histology: inferior outcome is associated with peripheral T-cell type and elevated lactate dehydrogenase, but not extent of cutaneous involvement
Ann. Onc.,
August 1, 2002;
13(8):
1290 - 1299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Nikolova, P. Musette, M. Bagot, L. Boumsell, and A. Bensussan
Engagement of ILT2/CD85j in Sezary syndrome cells inhibits their CD3/TCR signaling
Blood,
July 18, 2002;
100(3):
1019 - 1025.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Sarris, A. Phan, M. Duvic, J. Romaguera, P. McLaughlin, O. Mesina, K. King, L. J. Medeiros, G. Z. Rassidakis, B. Samuels, et al.
Trimetrexate in Relapsed T-Cell Lymphoma With Skin Involvement
J. Clin. Oncol.,
June 15, 2002;
20(12):
2876 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Zhang, P. Hazarika, X. Ni, D. A. Weidner, and M. Duvic
Induction of Apoptosis by Bexarotene in Cutaneous T-Cell Lymphoma Cells: Relevance to Mechanism of Therapeutic Action
Clin. Cancer Res.,
May 1, 2002;
8(5):
1234 - 1240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Breneman, M. Duvic, T. Kuzel, R. Yocum, J. Truglia, and V. J. Stevens
Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma
Arch Dermatol,
March 1, 2002;
138(3):
325 - 332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. L. Liu and Y. H. Kim
Bexarotene Gel: A Food and Drug Administration-Approved Skin-Directed Therapy for Early-Stage Cutaneous T-Cell Lymphoma
Arch Dermatol,
March 1, 2002;
138(3):
398 - 399.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Urosevic, J. Willers, B. Mueller, W. Kempf, G. Burg, and R. Dummer
HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas
Blood,
January 15, 2002;
99(2):
609 - 617.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Piekarz, R. Robey, V. Sandor, S. Bakke, W. H. Wilson, L. Dahmoush, D. M. Kingma, M. L. Turner, R. Altemus, and S. E. Bates
Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
Blood,
November 1, 2001;
98(9):
2865 - 2868.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. REDDY, C. OKADA, C. WONG, D. BAHLER, and R. LEVY
T Cell Antigen Receptor Vaccines for Active Therapy of T Cell Malignancies
Ann. N.Y. Acad. Sci.,
September 1, 2001;
941(1):
97 - 105.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Greer, M. C. Kinney, and T. P. Loughran Jr.
T Cell and NK Cell Lymphoproliferative Disorders
Hematology,
January 1, 2001;
2001(1):
259 - 281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
